Evidence map›Paper›PMID 37656380›Full record

ArticleCell biochemistry and biophysics2023

Infliximab Ameliorates Methotrexate-Induced Nephrotoxicity in Experimental Rat Model: Impact on Oxidative Stress, Mitochondrial Biogenesis, Apoptotic and Autophagic Machineries.

Eman F Wasfey, Marah Shaaban, Manalia Essam, Youssef Ayman, Salma Kamar, Tasneem Mohasseb, Rana Rozik, Huda Khaled, Mohamed Eladly, Mohammed Elissawi and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cell biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Eman F WasfeyBiochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Marah ShaabanDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Manalia EssamDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Youssef AymanDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Salma KamarDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Tasneem MohassebDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Rana RozikDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Huda KhaledDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mohamed EladlyDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Mohammed ElissawiDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Ahmed BassemDrug Design Program, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Shimaa Z ElshoraHistology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Sara M RadwanBiochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. sara.mostafa@pharma.asu.edu.eg.
Ain Shams University · EGAl-Azhar University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating data confirms that Methotrexate (MTX), a well-known immunosuppressive and anticancer drug, causes nephrotoxicity. Infliximab (INF), the inhibitor of tumor necrosis factor-alpha (TNF-α), was proven to have anti-inflammatory properties. Thus, it may have potential in preventing MTX-induced nephrotoxicity. Therefore, this study aimed to inspect the prospective nephroprotective effect of INF on MTX-induced rat nephrotoxicity through investigating the possible molecular mechanisms, including its interference with different death routes, oxidative stress as well as mitochondrial biogenesis. Rats received an INF intraperitoneal single dose of 7 mg/kg 72 h prior to a single 20 mg/kg MTX injection. MTX nephrotoxicity was demonstrated by significantly increased serum levels of the renal indicators urea and creatinine as well as renal inflammatory markers TNF-α and Interleukin-6 (IL-6) and the renal oxidative stress marker malondialdehyde (MDA), while renal antioxidant enzyme superoxide dismutase (SOD) was significantly decreased compared to control. INF injection prior to MTX markedly reversed these MTX-induced effects. Besides, MTX impaired mitochondrial biogenesis, while INF attenuated this impairment, as indicated by increased expression of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α). Finally, MTX triggered apoptotic and autophagic cascades in renal tissues as evidenced by reduced anti-apoptotic Bcl-2 protein expression as well as elevated expression of the pro-apoptotic protein Bax and both key regulators of autophagy; beclin-1 and LC-3, whereas INF pretreatment counteracted these apoptotic and autophagic effects of MTX. Summarily, these results suggest that INF provides protection against MTX-induced nephrotoxicity which could be elucidated by its antioxidant, anti-inflammatory, anti-apoptotic and anti-autophagic effects as well as upregulating mitochondrial biogenesis.

Indexed as

AntioxidantsMethotrexateAnimalsAnti-Inflammatory AgentsInfliximabKidneyOrganelle BiogenesisOxidative StressProspective StudiesRatsTumor Necrosis Factor-alphaAnti-Inflammatory AgentsAntioxidantsInfliximabMethotrexateTumor Necrosis Factor-alphaautophagyInfliximabMitochondrial biogenesis.MTX-induced nephrotoxicityPGC-1α

Identifiers

PMID37656380
PMCPMC10611839
OpenAlexW4386347494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.